Stock DNA
Pharmaceuticals & Biotechnology
CNY 46,687 Million (Large Cap)
14.00
NA
2.15%
-0.13
15.80%
2.19
Revenue and Profits:
Net Sales:
7,854 Million
(Quarterly Results - Jun 2025)
Net Profit:
880 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.6%
0%
-4.6%
6 Months
-14.85%
0%
-14.85%
1 Year
-17.42%
0%
-17.42%
2 Years
-2.77%
0%
-2.77%
3 Years
-14.73%
0%
-14.73%
4 Years
89.77%
0%
89.77%
5 Years
74.5%
0%
74.5%
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
16.23%
EBIT Growth (5y)
16.09%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
1.06
Tax Ratio
17.88%
Dividend Payout Ratio
50.04%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
21.37%
ROE (avg)
15.25%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
2.19
EV to EBIT
12.33
EV to EBITDA
9.48
EV to Capital Employed
2.36
EV to Sales
1.57
PEG Ratio
NA
Dividend Yield
2.15%
ROCE (Latest)
19.14%
ROE (Latest)
15.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
7,853.50
6,775.50
15.91%
Operating Profit (PBDIT) excl Other Income
1,161.10
1,895.90
-38.76%
Interest
27.90
21.70
28.57%
Exceptional Items
36.70
0.50
7,240.00%
Consolidate Net Profit
880.20
1,331.40
-33.89%
Operating Profit Margin (Excl OI)
108.80%
234.50%
-12.57%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 15.91% vs -12.95% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -33.89% vs 149.79% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
27,321.80
24,464.00
11.68%
Operating Profit (PBDIT) excl Other Income
5,109.60
4,377.80
16.72%
Interest
84.10
85.20
-1.29%
Exceptional Items
6.20
-83.80
107.40%
Consolidate Net Profit
3,777.70
3,173.50
19.04%
Operating Profit Margin (Excl OI)
154.10%
144.10%
1.00%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 11.68% vs 36.88% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 19.04% vs 27.09% in Dec 2023
About China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. 
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






